Antares Pharma, Inc. (NASDAQ:ATRS) – Research analysts at Zacks Investment Research issued their Q2 2018 earnings per share estimates for Antares Pharma in a research note issued to investors on Thursday, May 10th, according to Zacks Investment Research. Zacks Investment Research analyst J. Vandermosten expects that the specialty pharmaceutical company will post earnings per share of ($0.03) for the quarter. Zacks Investment Research also issued estimates for Antares Pharma’s Q3 2018 earnings at ($0.02) EPS and Q4 2018 earnings at ($0.02) EPS.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01). The company had revenue of $12.70 million for the quarter, compared to the consensus estimate of $12.85 million. Antares Pharma had a negative return on equity of 52.74% and a negative net margin of 32.96%.
Shares of NASDAQ ATRS opened at $2.59 on Friday. The firm has a market cap of $403.04 million, a P/E ratio of -23.55 and a beta of 0.19. Antares Pharma has a 12-month low of $2.46 and a 12-month high of $2.52. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.39 and a current ratio of 2.94.
Several institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. lifted its stake in shares of Antares Pharma by 5.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 560,936 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after buying an additional 27,360 shares in the last quarter. California Public Employees Retirement System raised its holdings in shares of Antares Pharma by 4.1% in the third quarter. California Public Employees Retirement System now owns 972,694 shares of the specialty pharmaceutical company’s stock valued at $3,152,000 after purchasing an additional 38,394 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Antares Pharma by 34.9% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 180,666 shares of the specialty pharmaceutical company’s stock valued at $360,000 after purchasing an additional 46,766 shares during the last quarter. MetLife Investment Advisors LLC raised its holdings in shares of Antares Pharma by 281.1% in the first quarter. MetLife Investment Advisors LLC now owns 71,731 shares of the specialty pharmaceutical company’s stock valued at $158,000 after purchasing an additional 52,911 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Antares Pharma in the fourth quarter valued at about $117,000. 35.74% of the stock is currently owned by hedge funds and other institutional investors.
In other Antares Pharma news, Director Jacques Gonella sold 200,000 shares of the firm’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $2.42, for a total value of $484,000.00. Following the transaction, the director now directly owns 11,686,413 shares of the company’s stock, valued at $28,281,119.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 700,000 shares of company stock worth $1,725,000 over the last ninety days. Insiders own 11.60% of the company’s stock.
About Antares Pharma
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.